Israel state records י"ג בשבט התשס"ח January 20, 2008

מולוקולת אגוניסטיות דמויות אינסולין כגורמי גדילה	INSULIN-LIKE GROWTH FACTOR AGONIST MOLECULES
[54]
	31.03.1998					[22]
	US	[33]	04.04.1997	[32]	08/825852	[31]
Int. Cl.8 A61K 038/00, 038/17, A61P 003/04, 003/10, 009/00, 013/12, 025/00, C07K 007/06, 007/08, 014/00, 014/47, 014/65, 019/00, C12N 015/11, G01N 033/566, 033/68						[51]
			GENENTECH, INC., U.S.A. IAIN C.A.F. ROBINSON, UNITED KINGDOM			[71]
	WO/1998/045427					[87]
ריינהולד כהן ושותפיו, רחוב אחד העם 21 , ת.ד. 4060, תל אביב			REINHOLD COHN AND PARTNERS, 21 AHAD HA'AM ST., P.O.B. 4060, TEL AVIV 61040			[74]

[57] A peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SQE ID NO:15, and SEQ ID NO:16.

__________

132087			[21][11]
חלקיק וקטרו רטרו–ויראלי בעל חלבון מעטפת חלבון רטרו–ויראלי מותאם לקישור לקולאגן, שיטה להפקתו, ושימוש בו להכנת תרופה לביטוי גורם ריפויי בבעל–חיים			RETROVIRAL VECTOR PARTICLE HAVING A RETROVIRAL ENVELOPE PROTEIN MODIFIED TO BIND COLLAGEN, METHOD OF GENERATING IT AND USE THEREOF IN PREPARING A MEDICAMENT FOR EXPRESSING A THERAPEUTIC AGENT IN AN ANIMAL			[54]
	08.04.1998					[22]
	US	[33]	10.04.1997	[32]	08/837223	[31]
Int. Cl.8 A61K 048/00, C07K 014/15, C12N 005/10, 015/48, 015/867						[51]
			UNIVERSITY OF SOUTHERN CALIFORNIA, U.S.A.			[71]
	WO/1998/044938					[87]
לוצאטו את לוצאטו, גן תעשייה, עומר , ת.ד. 5352, באר שבע			LUZZATTO & LUZZATTO, INDUSTRIAL PARK, OMER, P.O.B. 5352, BEER-SHEVA 84152			[74]

[57] A retroviral vector particle having a modified retroviral envelope protein for targeting the vector particle to an extracellular matrix component, wherein said envelope protein is modified to include a targeting polypeptide including a binding region which binds to the extracellular matrix component collagen.

__________

132239			[21][11]
נוגדני פקטור גדילה אנדותליים אנטי–וסקולאריים אנושיים, שיטה להכנת נוגדנים אנושיים כאלו ושימוש בהם בהכנת תרופות לעיכוב צמיחת גידולים			HUMANIZED ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR ANTIBODIES, A METHOD FOR PREPARING SUCH HUMANIZED ANTIBODIES AND USE THEREOF IN THE PREPARATION OF MEDICAMENTS FOR INHIBITING TUMOR GROWTH			[54]
	03.04.1998					[22]
	US	[33]	07.04.1997	[32]	08/833504	[31]
Int. Cl.8 A61K 039/395, A61P 035/00, C07K 016/22, 016/46, C12N 015/13, 015/66						[51]
			GENENTECH, INC., U.S.A.			[71]
	WO/1998/045332					[87]
ש. הורוביץ ושות', בית ציון, שדרות רוטשילד 41-45, תל אביב			S. HOROWITZ & CO., ZION HOUSE, 41-45 ROTHSCHILD BLVD., TEL AVIV 65784			[74]

[57] A humanized anti-vascular endothelial growth factor antibody, wherein the complementarity determining regions (CDRs) of a non-human antibody are grafted onto a human framework comprising the V_Lk subgroup I (V_LkI) framework of SEQ ID NO:7 and the V_H subgroup III (V_HIII) framework of SEQ ID NO:10, in which at least one of representively numbered residues 4 and 71 of the V_L domain is substituted with a different amino acid, and at least three of representatively numbered residues 37, 67, 69, 71, 73, 75, 76, 78 and 94 of V_H domain are substituted with a different amino acid, and wherein residue 46 of the V_L domain is optionally substituted with the amino acid valine, and wherein the residue numbering is according to Kabat numbering as shown in Figure 1 of the specification.

__________

132560			[21][11]
שיטה לייצור נוגדנים רב–יחודיים בעלי מרכיבים הטרומולטימרים ומשותפים			METHOD FOR MAKING MULTISPECIFIC ANTIBODIES HAVING HETEROMULTIMERIC AND COMMON COMPONENTS			[54]
	30.04.1998					[22]
	US	[33]	02.05.1997	[32]	08/850058	[31]
	US		24.06.1997		60/050661
Int. Cl.8 A61K 039/395, 039/44, C07K 016/00, 016/46, C12N 015/13						[51]
			GENENTECH, INC., U.S.A.			[71]
	WO/1998/050431					[87]
ריינהולד כהן ושותפיו, רחוב אחד העם 21 , ת.ד. 4060, תל אביב			REINHOLD COHN AND PARTNERS, 21 AHAD HA'AM ST., P.O.B. 4060, TEL AVIV 61040			[74]

[57] A method of preparing a multispecific antibody comprising at least two different binding domains, wherein a first binding domain binds a first molecule and a second binding domain binds a second molecule different from said first molecule, each binding domain comprises (i) a heavy chain variable domain which is part of a polypeptide which further comprises a multimerization domain and (ii) a variable domain of a light chain, the first binding domain comprises a first heavy chain variable domain of a first polypeptide, the second binding domain comprises a second heavy chain variable domain of second polypeptide, and the first and second heavy chain variable domains, are different, and wherein either each light chain variable domain is identical, or the multispecific antibody comprises a first light chain variable domain and a second light chain variable domain, the first and second light chain variable domains differ from one another but have at least 80% amino acid sequence identity, and said first binding domain binds said first molecule whether said first binding domain comprises the first light chain variable domain or the second light chain variable domain, and said second binding domain binds said second molecule whether said second binding domain comprises the second light chain variable domain or the first light chain variable domain, the method comprising the steps of:

(i) culturing a host cell comprising nucleic acid encoding said polypeptides and light chain or light chains, wherein the culturing is such that the nucleic acid is expressed and the polypeptides and light chain or light chains produced; and

(ii) recovering the multispecific antibody from the host cell culture.

__________

134298			[21][11]